Skip to main content
. 2015 May;32(Suppl 4):57S–65S.

Figure 2.

Figure 2

Mitogen-Activated Protein Kinase Pathway: Molecular Targets of Therapy

The BRAF gene is a downstream receptor of the NRAS gene and causes sequential kinase enzyme activation (MEK, ERK) that leads to tumorigenesis. This pathway can be targeted by using BRAF or MEK inhibitors. The NRAS gene can also be activated by c-KIT gene mutation and can be a target of therapy.